Bovine Lactoferrin Prevents Invasive Fungal Infections in Very Low Birth Weight Infants: A Randomized Controlled Trial

Manzoni, Paolo; Stolfi, Ilaria; Messner, Hubert; Cattani, Silvia; Laforgia, Nicola; Romeo, Mario; Bollani, Lina; Rinaldi, Matteo; Gallo, Eugenia; Quercia, Michele; Maule, Milena; Mostert, M.; Decembrino, Lidia; Magaldi, Rosario; Mosca, Fabio; Vagnarelli, Federica; Memo, Luigi; Betta, Pasqua; Stronati, Mauro; Farina, Daniele

doi:10.1542/peds.2011-0279

Cited by 143 publications

(95 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 The incidence of fungal sepsis was also reduced by bovine lactoferrin supplementation in this high-risk population. 22 Similar clinical benefits may apply in adult populations. Treatment of acute bacteremia in adult intensive care patients using recombinant human lactoferrin reduced all-cause mortality by 46% relative to placebo treatment in a multicenter trial.…”

Section: Antimicrobial Properties Of Lactoferrinmentioning

confidence: 95%

Clinical applications of bioactive milk components

Hill

Newburg

2015

Nutrition Reviews

View full text Add to dashboard Cite

Milk represents a unique resource for translational medicine: It contains a rich pool of biologically active molecules with demonstrated clinical benefits. The ongoing characterization of the mechanistic process through which milk components promote development and immunity has revealed numerous milk-derived compounds with potential applications as clinical therapies in infectious and inflammatory disease, cancer, and other conditions. Lactoferrin is an effective antimicrobial and antiviral agent in high-risk patient populations and a potentially potent adjuvant to chemotherapy in lung cancer. Enteric nutrition formulas supplemented with transforming growth factor b, a milk cytokine, have been shown to promote remission in pediatric Crohn's disease. A number of milk glycans, including human milk oligosaccharides, show promise in preclinical studies as antimicrobial and antiinflammatory agents. While active preclinical investigations of human milk may soon result in large-scale production of human milk molecules, bovine milk components in many instances represent a practical source of bioactive milk compounds for use in clinical trials. This review summarizes current efforts to translate the compounds derived from human and bovine milk into effective clinical therapies. These efforts suggest a common pathway for the translation of milk-derived compounds into clinical applications.

show abstract

Section: Antimicrobial Properties Of Lactoferrinmentioning

confidence: 95%

Clinical applications of bioactive milk components

Hill

Newburg

2015

Nutrition Reviews

View full text Add to dashboard Cite

show abstract

“…In the secondary analysis, Manzoni et al [34] further showed that prophylactic oral administration of BLF reduced the incidence of invasive fungal sepsis, though there was no effect reported on colonization. In other study conducted from our India, Kaur et al [35] followed up 121 low birth weight infants and reported significant reduction in the incidence of LOS in the BLF group as compared to the placebo group [n=2/59 versus n=9/62, p=0.033).…”

Section: Neonatal Sepsis and Lfmentioning

confidence: 99%

Lactoferrin and Its Role in Neonatology: A Review Article

Sharma¹

2015

JPNC

View full text Add to dashboard Cite

Lactoferrin (LF) is a glycoprotein, which is present in milk of mammals. It has been proven to plays a very important role in innate immune host defences. It is well known that Neonatal sepsis and necrotizing enterocolitis (NEC) are responsible for significant morbidity and mortality in the new-born, especially in VLBW (1500 grams at birth) infants. The ill effects of sepsis and NEC persist in spite of appropriate and effective antibiotic therapy and have been associated with poor long term outcome. In the few recent trials which have been conducted around the globe, in field of neonatology, role of LF in prevention of neonatal sepsis and NEC has been strengthened. Furthermore many trials are underway and only future may provide a definite answer of LF role in sepsis and NEC. This review article has been written to through some light on the recent work that has already been done, to strengthen the role of LF in neonatal sepsis and the work that is still under process.

show abstract

“…Manzoni et al studied 472 newborns weighing 1,500 g or less in neonatal ICUs at 11 facilities [ 29 ]. They compared a group that received lactoferrin to a placebo control group and found that administration of lactoferrin signifi cantly suppressed the occurrence of tardive septicemia, signifi cantly reduced fungal infection, and reduced mortality.…”

Section: Pharmacological Nutrients and Clinical Studies Related To Whmentioning

confidence: 99%